MariMed Q2 10-Q: Record Revenue, Wider Loss, and $7M in Disputed IRS Liens
MRMD is trading near its 52-week low of $0.061 (6.6% above the low).
Summary
MariMed reported record Q2 revenue of $41.9M but a wider net loss of $3.6M. The 10-Q also disclosed $7M in disputed IRS tax liens and a $786K tax benefit from cannabis rescheduling.
Key Events · Earnings and Guidance · MRMD
-
Record Revenue, Wider Loss
Q2 revenue rose 6.1% to $41.9M, but net loss widened to $3.6M from $1.4M a year ago, driven by higher cost of revenue and operating expenses.
-
IRS Tax Liens Total $7M
The company disclosed IRS liens of approximately $1M against FSC and $6M against the company for prior tax periods, both being disputed through Collection Due Process hearings.
-
Schedule III Tax Benefit
The DOJ's April 2026 rescheduling of cannabis to Schedule III reduced income tax expense by approximately $786,000 in Q2 2026.
-
Series B Restructuring Completed
The February 2026 restructuring exchanged $14.2M of Series B obligations for $8M in new notes and 26.9M shares of new preferred stock, recognizing a $0.7M gain.
Analysis · MRMD · Life Sciences
MariMed's Q2 10-Q confirms record revenue of $41.9M but a wider net loss of $3.6M, driven by margin pressure and higher operating costs. The filing reveals $7M in disputed IRS tax liens and a $786K tax benefit from the DOJ's Schedule III reclassification. While the company states it has sufficient cash for the next 12 months, the combination of rising debt, tax disputes, and continued losses keeps pressure on the balance sheet.
At the time of this filing, MRMD was trading at $0.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $26M. The 52-week trading range was $0.06 to $0.23. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.